A third local life sciences company, Intrexon Corp., raised $160 million in its August IPO.

GlycoMimetics' lead drug candidate, GMI-1070, is in the midst of mid-stage trials as a treatment for vaso-occlusive crisis, a complication of sickle cell disease. GMI-1070 is being developed under a two-year-old collaboration with Pfizer worth as much as $340 million.

The company plans to trade on the NASDAQ under the ticker symbol GLYC. Like MacroGenics and Cvent (and Twitter) before it, GlycoMimetics filed a confidential draft registration statement with the SEC in late August before publicly rolling out its S-1 filing on Friday, a process allowed under the JOBS Act.